Dilini Christina Ranasinghe: Paediatric TPE Is Not Simply Adult TPE in a Smaller Patient
Dilini Christina Ranasinghe, Registrar in Transfusion Medicine at National Blood Centre, shared a post on LinkedIn:
“Paediatric TPE is not simply ‘adult TPE in a smaller patient’
Therapeutic plasma exchange (TPE) in children requires a different level of procedural planning and vigilance.
Key paediatric considerations include:
Extracorporeal volume and blood priming
In children, the circuit volume may represent a significant proportion of total blood volume. Initiating TPE with a saline-primed circuit can lead to haemodilution and hypotension. Blood priming with compatible red cells helps maintain haemodynamic stability and improves tolerance.
Vascular access and line position
Central lines may be malpositioned into unintended vessels or advanced too far due to smaller anatomy. This can lead to poor flow, ineffective exchange, or arrhythmias if the tip irritates the atrial wall — making confirmation of position with imaging essential before starting TPE.
Continuous rather than intermittent exchange
Children tolerate rapid intravascular shifts poorly. A controlled, continuous exchange allows gradual removal and replacement, improving haemodynamic stability.
Continuous monitoring and vigilance
With limited physiological reserve, deterioration can be rapid.
Close monitoring of haemodynamics, electrolytes (especially calcium), access pressures, and clinical status is essential.
Early recognition of subtle changes is key to preventing significant complications.
Team coordination
Safe paediatric TPE requires coordination between paediatric specialties, transfusion medicine, ICU teams when required, and microbiology, across all staff categories — ensuring safe delivery in different care settings.
In paediatric TPE, safety lies in anticipating physiological changes and responding before instability develops.”

Stay updated with Hemostasis Today.
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery
-
Aug 31, 2026, 14:06Khalid Alfawaz: Signed Consent Doesn’t Always Mean Informed
-
Aug 31, 2026, 14:03Adil Aftab: Anticoagulation in CKD – Key Updates from the 2026 ESC Guidelines
-
Aug 31, 2026, 14:01Isa Oboirien: Why Might Factor XI Inhibition Work Differently in Stroke and ACS?
-
Aug 31, 2026, 13:55Mike Morrissey: Advancing Europe’s Cardiovascular Health Agenda at ESC Congress 2026
-
Aug 31, 2026, 13:44Penilla Gunther: Patient Voices Take Center Stage in Cardiovascular Prevention at ESC Congress 2026
-
Aug 31, 2026, 13:42Mohamed Saleh Gomaa: Master the Latest in PE Management
-
Aug 31, 2026, 13:38Lyn Kleinbach-Reilly: A New Standard for Coagulation Testing in Neonatal Care
-
Aug 31, 2026, 13:36Rafael Gomes: Can Prasugrel Replace Ticagrelor in ACS Treatment?